

Superiority of  $^{68}\text{Ga}$ -DOTATATE over  $^{18}\text{F}$ -FDG and anatomic MRI in the diagnosis of pheochromocytoma and paraganglioma in succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population

European Journal of Nuclear Medicine and Molecular Imaging  
45, 787-797

DOI: 10.1007/s00259-017-3896-9

Citation Report

#	ARTICLE	IF	CITATIONS
1	Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine. <i>Clinical Nuclear Medicine</i> , 2018, 43, e392-e399.	0.7	22
2	The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. <i>Journal of Clinical Medicine</i> , 2018, 7, 280.	1.0	104
4	Advances in adrenal tumors 2018. <i>Endocrine-Related Cancer</i> , 2018, 25, R405-R420.	1.6	16
5	Neuroendocrine Tumor Diagnosis and Management: <sup>68</sup> Ga-DOTATATE PET/CT. <i>American Journal of Roentgenology</i> , 2018, 211, 267-277.	1.0	133
6	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. <i>Frontiers in Endocrinology</i> , 2018, 9, 515.	1.5	82
7	Performance of <sup>68</sup> Ga-DOTA- <sup>68</sup> Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 369-376.	2.8	137
8	Neuroendocrine Tumors in Pediatrics. <i>Global Pediatric Health</i> , 2019, 6, 2333794X1986271.	0.3	12
9	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137.	3.3	208
10	<sup>11</sup> C-hydroxy-ephedrine-PET/CT in the Diagnosis of Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2019, 11, 847.	1.7	18
11	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505.	1.7	120
12	Biochemically silent sympathetic Paraganglioma, Pheochromocytoma or Metastatic Disease in SDHD mutation carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5421-5426.	1.8	8
13	Molecular imaging and therapy of somatostatin receptor positive tumors. <i>Clinical Imaging</i> , 2019, 56, 146-154.	0.8	28
14	Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Radiology Reports</i> , 2019, 7, 1.	0.4	0
15	Concurrent Metastatic Pheochromocytomas and Lung Adenocarcinoma on 18F-FDG and <sup>68</sup> Ga-DOTATATE PET/CT Images. <i>Clinical Nuclear Medicine</i> , 2019, 44, 754-756.	0.7	4
16	Pediatric applications of Dotatate: early diagnostic and therapeutic experience. <i>Pediatric Radiology</i> , 2020, 50, 882-897.	1.1	17
17	Multimodality Imaging in Cardiac Masses. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2412-2414.	2.3	7
18	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1443-1456.	0.3	190
19	Non-18F-Fluorodeoxyglucos PET Tracers in Pediatric Disease. <i>PET Clinics</i> , 2020, 15, 241-251.	1.5	1

#	ARTICLE	IF	CITATIONS
20	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1051-1063.	1.2	30
21	Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 48-52.	0.6	9
22	The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas. <i>Nuclear Medicine Communications</i> , 2020, 41, 169-174.	0.5	7
23	PET/MR in Head and Neck Cancer – An Update. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 26-38.	2.5	30
24	Metastatic Pheochromocytomas and Abdominal Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1937-e1952.	1.8	41
25	Pheochromocytoma/Paraganglioma, Medullary Thyroid Carcinoma, and Hereditary Endocrine Neoplasia Syndromes. , 2021, , 491-527.		1
26	Pheochromocytoma and Paraganglioma. , 2021, , 101-137.		0
27	The role of [68Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRα gastrointestinal stromal tumours (GIST). <i>EJNMMI Research</i> , 2021, 11, 5.	1.1	4
28	Imagen 3mica. Hallazgos en la PET con 68Ga-DOTA-TOC asociados a la detección de la mutación del gen succinato deshidrogenasa B (SDHB) en el cribado del feocromocitoma/paraganglioma hereditario. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, , .	0.0	0
29	Genetics of pheochromocytoma and paraganglioma. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 283-290.	1.2	22
30	Genetic and clinical aspects of paediatric pheochromocytomas and paragangliomas. <i>Clinical Endocrinology</i> , 2021, 95, 117-124.	1.2	10
31	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. <i>Frontiers in Endocrinology</i> , 2021, 12, 625312.	1.5	25
32	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. <i>Pancreas</i> , 2021, 50, 469-493.	0.5	55
33	Pheochromocytomas and paragangliomas. <i>Current Opinion in Pediatrics</i> , 2021, Publish Ahead of Print, 430-435.	1.0	5
34	Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239.	8.9	127
35	Imaging of Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1033-1042.	2.8	50
36	Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 31-37.	0.6	9
37	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. <i>Endocrine-Related Cancer</i> , 2019, 26, R627-R652.	1.6	72

#	ARTICLE	IF	CITATIONS
38	Diagnosis and Management of Endocrine Hypertension in Children and Adolescents. Current Pharmaceutical Design, 2020, 26, 5591-5608.	0.9	5
39	The utility of <sup>68</sup> Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma in children and adolescents— a single-center experience. Journal of Pediatric Endocrinology and Metabolism, 2021, 34, 109-119.	0.4	7
40	The utility of <sup>68</sup> ga-dotatate pet/ct in localizing primary/metastatic pheochromocytoma and paraganglioma: Asian Indian experience. Indian Journal of Endocrinology and Metabolism, 2021, 25, 410.	0.2	4
41	Quantitative analysis of <sup>68</sup> Ga-DOTA(0)-Tyr(3)-octreotate positron emission tomography/computed tomography imaging for the differential diagnosis of primary pheochromocytoma and paraganglioma. Quantitative Imaging in Medicine and Surgery, 2022, 12, 2427-2440.	1.1	1
42	Integrated PET/MRI With <sup>68</sup> Ga-DOTATATE and <sup>18</sup> F-FDG in Pheochromocytomas and Paragangliomas. Clinical Nuclear Medicine, 2022, 47, 299-304.	0.7	5
43	Wide Variability in Catecholamine Levels From Adrenal Venous Sampling in Primary Aldosteronism. Journal of Surgical Research, 2022, 277, 1-6.	0.8	2
44	Imagenomics. Findings in PET with <sup>68</sup> Ga-DOTA-TOC associated with the detection of the mutation of the succinate dehydrogenase B (SDHB) gene in the screening of hereditary pheochromocytoma/paraganglioma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, , .	0.1	0
45	Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma—Experiences From the GPOH-MET Registry. Frontiers in Endocrinology, 0, 13, .	1.5	4
46	Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches. Frontiers in Endocrinology, 0, 13, .	1.5	6
47	Comparison of the Sensitivity of <sup>68</sup> Ga-DOTATATE PET/CT with Other Imaging Modalities in Detecting Head and Neck Paraganglioma: Experience from Western India. World Journal of Nuclear Medicine, 2022, 21, 184-191.	0.3	1
48	New Biology of Pheochromocytoma and Paraganglioma. Endocrine Practice, 2022, 28, 1253-1269.	1.1	8
49	Primary Functioning Hepatic Paraganglioma Treated by Laparoscopy: A Case Report. Journal of Clinical Medicine, 2022, 11, 7282.	1.0	0
50	Clinical utility of nuclear imaging in the evaluation of pediatric adrenal neoplasms. Frontiers in Oncology, 0, 12, .	1.3	1
51	Imaging Recommendations for Theranostic PET-CT in Oncology. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	0
52	Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Lancet Diabetes and Endocrinology,the, 2023, 11, 345-361.	5.5	15
53	Surgical strategies of complicated pheochromocytomas/paragangliomas and literature review. Frontiers in Endocrinology, 0, 14, .	1.5	1
58	Secondary Hypertension: Pheochromocytoma and Paraganglioma. , 2024, , 187-197.		0
59	Genetics, Biology, Clinical Presentation, Laboratory Diagnostics, and Management of Pediatric and Adolescent Pheochromocytoma and Paraganglioma. , 2023, , 107-125.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------